MRNA Comprehensive Income History: $-2.77B (FY2025)

Fiscal year	Q1	Q2	Q3	Q4
FY26	−$1.4B−43.3%	Not reported	Not reported	Not reported
FY25	−$951M+17.5%	−$812M+35.0%	−$196M−306.3%	−$808M+29.2%
FY24	−$1.2B−733.5%	−$1.2B+9.2%	$95M+102.7%	−$1.1B−474.1%
FY23	$182M−94.8%	−$1.4B−164.3%	−$3.6B−483.9%	$305M−78.9%
FY22	$3.5B+186.9%	$2.1B−23.4%	$932M−72.2%	$1.4B−70.0%
Share	27%	25%	20%	29%

01—History

Comprehensive Income History

Year-over-year comparison from 10-K annual reports · Dashed line: constant growth FY2020–FY2025. Drag across the bars to change the range.

−$2.77B

YoY changeLargest recent move−46.0%in FY20Latest +19.8%

2 older moves run past ±150% (largest +1732.0%); point at, tap or drag across the bars to read one.

02—Ledger

Comprehensive Income, period by period

Period	Value	Change	Source
FY2025	−$2.77B	+19.8%	10-K
FY2024	−$3.45B	+22.8%	10-K
FY2023	−$4.47B	−155.7%	10-K
FY2022	$8.02B	−34.2%	10-K
FY2021	$12.18B	+1732.0%	10-K
FY2020	−$746.0M	−46.0%	10-K
FY2019	−$511.0M	−32.8%	10-K
FY2018	−$384.9M	−50.0%	10-K
FY2017	−$256.7M	−18.8%	10-K
FY2016	−$216.0M	—	10-K

03—Questions

What is comprehensive income?

Comprehensive income includes net income plus other comprehensive items like foreign currency adjustments and unrealized investment gains or losses.

What is Moderna, Inc.'s current comprehensive income?

Moderna, Inc. (MRNA) annual comprehensive income for 2025 was $-2.77B, a 19.75% increase from 2024. Moderna, Inc. comprehensive income for the quarter ending March 31, 2026 was $-1.36B.

What was Moderna, Inc.'s comprehensive income in 2024?

Moderna, Inc. annual comprehensive income for 2024 was $-3.45B, a 22.81% increase from 2023.

What was Moderna, Inc.'s comprehensive income in 2023?

Moderna, Inc. annual comprehensive income for 2023 was $-4.47B, a 155.73% decline from 2022.

Company: Moderna, Inc.
Ticker: MRNA
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)

Moderna, Inc. Comprehensive Income 2016-2026 | MRNA

Key Statistics